Vitamin C vs allopurinol
Withdrawals due to adverse events · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
- no estimate extracted1 study · 40 participantsLow
Findings
What do systematic reviews say?
3,234 questions · 3,357 findings · 396 reviews
No studies found 803 · 23.9%GRADE not reported 270 · 8%Very low 757 · 22.5%Low 859 · 25.6%Moderate 486 · 14.5%High 182 · 5.4%
Summary of Findings Table ‐ Ibuprofen 300 mg vs paracetamol
Median (mean) time to use of rescue medication · health problem or population
1 finding from 1 review
- Single‐dose intravenous ibuprofen for acute postoperative pain in adults 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 151 participantsVery low
Summary of Findings Table ‐ Ibuprofen 300 mg vs paracetamol
Number of participants reporting an adverse event · health problem or population
It is very uncertain whether summary of Findings Table ‐ Ibuprofen 300 mg changes number of participants reporting or experiencing any adverse event compared with active comparator (acetaminophen) (very low certainty).
1 finding from 1 review
- Single‐dose intravenous ibuprofen for acute postoperative pain in adults 2021 · Cochrane Headline outcomes onlyRR 1.27 [1.02, 1.59]1 study · 151 participantsVery low
Summary of Findings Table ‐ Ibuprofen 300 mg vs paracetamol
Number of participants experiencing any serious adverse events · health problem or population
1 finding from 1 review
- Single‐dose intravenous ibuprofen for acute postoperative pain in adults 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 1 participantsVery low
Summary of Findings Table ‐ Ibuprofen 300 mg vs paracetamol
At least 50% reduction in pain · health problem or population
It is very uncertain whether summary of Findings Table ‐ Ibuprofen 300 mg changes number of participants with at least 50% pain relief at 4 hours compared with active comparator (acetaminophen) (very low certainty).
2 findings from 1 review
- Single‐dose intravenous ibuprofen for acute postoperative pain in adults 2021 · Cochrane Headline outcomes onlyRR 0.91 [0.58, 1.43]1 study · 151 participantsVery low
- Single‐dose intravenous ibuprofen for acute postoperative pain in adults 2021 · Cochrane Headline outcomes onlyRR 1.03 [0.64, 1.66]1 study · 151 participantsVery low
Summary of Findings Table ‐ Ibuprofen 300 mg vs paracetamol
Number of participants using rescue medication over 4 to 6 hours postinterventions · health problem or population
The review found no eligible studies for this question.
1 finding from 1 review
- Single‐dose intravenous ibuprofen for acute postoperative pain in adults 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Intervention not reported
All intervention options · people with first recurrence of glioblastoma Interventions: bevacizumab (BEV), BEV + lomustine (LOM), regorafenib (REG), fotemustine…
The review found no eligible studies for this question.
1 finding from 1 review
- Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Intervention not reported
BEV+IRI (1 RCT, 79 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention leads to higher BEV+IRI (1 RCT, 79 participants) (high certainty).
1 finding from 1 review
- Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyRR 2.22 [1.19, 4.18]1 study · 79 participantsHigh
Intervention not reported
BEV+VB111 (1 RCT, 128 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention leads to higher BEV+VB111 (1 RCT, 128 participants) (high certainty).
1 finding from 1 review
- Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyRR 3.77 [2.25, 6.33]1 study · 111 participantsHigh
Intervention not reported
BEV+TRC 105 (1 RCT, 49 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention leads to higher BEV+TRC 105 (1 RCT, 49 participants) (high certainty).
1 finding from 1 review
- Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyRR 6.86 [2.55, 18.41]1 study · 105 participantsHigh
Intervention not reported
All intervention options · people with first recurrence of glioblastoma Interventions: bevacizumab (BEV), BEV + lomustine (LOM), regorafenib (REG), BEV + irinotecan…
The review found no eligible studies for this question.
1 finding from 1 review
- Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Intervention not reported
Outcomes (5 RCTs, 1024 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
1 finding from 1 review
- Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyno estimate extracted5 studies · 1024 participantsGRADE not reported
Intervention not reported
BEV(8 RCTs; 498 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
1 finding from 1 review
- Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyno estimate extracted8 studies · 498 participantsGRADE not reported
Intervention not reported
FOM (1 RCT, 32 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in FOM (1 RCT, 32 participants); GRADE not reported.
1 finding from 1 review
- Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyRR 0.44 [0.11, 1.72]1 study · 32 participantsGRADE not reported
Intervention not reported
BEV+HSPPC96 1 RCTs; 53 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in BEV+HSPPC96 1 RCTs; 53 participants) (low certainty).
1 finding from 1 review
- Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyRR 1.01 [0.33, 3.1]1 study · 96 participantsLow
Intervention not reported
BEV+ONA(1 RCT; 64 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in BEV+ONA(1 RCT; 64 participants) (low certainty).
1 finding from 1 review
- Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyRR 1.17 [0.57, 2.39]1 study · 64 participantsLow
Intervention not reported
BEV+CAB (1 RCT; 58 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in BEV+CAB (1 RCT; 58 participants) (low certainty).
1 finding from 1 review
- Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyRR 1.27 [0.61, 2.66]1 study · 58 participantsLow
Intervention not reported
BEV+DAS (2 RCTs, 83 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in BEV+DAS (2 RCTs, 83 participants) (high certainty).
1 finding from 1 review
- Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis 2021 · Cochrane Headline outcomes onlyRR 0.52 [0.69, 3.34]2 studies · 83 participantsHigh
Oral misoprostol vs vaginal dinoprostone
Uterine hyperstimulation with fetal heart rate changes · women in the third trimester for induction of labour.
Oral misoprostol may leads to lower uterine hyperstimulation with fetal heart rate changes compared with vaginal dinoprostone (low certainty).
1 finding from 1 review
- RR 0.49 [0.4, 0.59]11 studies · 9084 participantsLow
Oral misoprostol vs vaginal dinoprostone
Oxytocin augmentation · women in the third trimester for induction of labour.
It is very uncertain whether oral misoprostol changes oxytocin augmentation compared with vaginal dinoprostone (very low certainty).
1 finding from 1 review
- RR 0.9 [0.75, 1.09]12 studies · 9451 participantsVery low